ES2535681T3 - Nuevos complejos Tat, y vacunas que los comprenden - Google Patents

Nuevos complejos Tat, y vacunas que los comprenden Download PDF

Info

Publication number
ES2535681T3
ES2535681T3 ES05729962.0T ES05729962T ES2535681T3 ES 2535681 T3 ES2535681 T3 ES 2535681T3 ES 05729962 T ES05729962 T ES 05729962T ES 2535681 T3 ES2535681 T3 ES 2535681T3
Authority
ES
Spain
Prior art keywords
tat
peptide
region
vaccines
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05729962.0T
Other languages
English (en)
Inventor
Barbara Ensoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Superiore di Sanita ISS
Original Assignee
Istituto Superiore di Sanita ISS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Superiore di Sanita ISS filed Critical Istituto Superiore di Sanita ISS
Application granted granted Critical
Publication of ES2535681T3 publication Critical patent/ES2535681T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un complejo que comprende primer y segundo péptidos, comprendiendo el primer péptido el bucle V3 de la gp120, y en donde el bucle V3 está unido a una región de unión en el segundo péptido, comprendiendo el segundo péptido dicha región de unión, región que comprende al menos los restos 21-40 y 46-58 de Tat (SEC ID NO 1), o al menos dichos restos con una mutación puntual adicional, con lo que Cys 22 de Tat es sustituido por glicina, siendo dicha Tat mutante en Cys22 capaz de unirse a una región en la gp120 que comprende los restos 301-419 de la gp120 (SEC ID NO. 2).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
5
10
15
20
25
30
35
E05729962
27-04-2015
mostraban una unión dependiente de la dosis del péptido del bucle V3 a Tat inmovilizada (Tabla Ibis).
TABLA 1
Anticuerpos
Revestimiento
Incubación anti-Tat anti-V3
ninguno
tampón 0,132 DO 0,15 DO
ninguno
Tat 0,431 DO 0,122 DO
V3 (500 ng)
tampón 0,277 DO 3 DO
V3 (500 ng)
Tat 1 DO 3 DO
TABLA 1 bis Pocillos revestidos con Tat (100 ng) y bloqueados con albúminas de suero bovino (BSA) (100 imagen8g)
Cantidades del péptido del bucle V3 (ng)
0 50 100 200 500
Anticuerpo anti V3
0,119 DO 0,181 DO 0,285 DO 0,435 DO 0,787 DO
Anticuerpo anti TAT
1,438 DO 1,545 DO 1,51 DO 1,515 DO 1,567 DO
Pocillos revestidos con BSA (BSA) (100 imagen9g) Anticuerpo anti V3 0,103 DO 0,124 DO 0,148 DO 0,142 DO 0,179 DO
EJEMPLO 3
Tat es reconocida por anticuerpos dirigidos contra el correceptor CCR5 de VIH
Dado que el bucle V3 de la gp120 parece ser el determinante fundamental para la elección del correceptor y la utilización por cepas de VIH, se realizaron experimentos para determinar si la capacidad de Tat de unirse al péptido V3 se debía a mimetismo por Tat de moléculas del correceptor. Con este fin, se usaron anticuerpos monoclonales dirigidos contra los principales correceptores de VIH-1 (CCR5 y CXCR4) (Pharmingen) en un ensayo ELISA para determinar si podían reconocer Tat, o péptidos de Tat que constan de secuencias de y/o dominios estructurales y funcionales de Tat específicos. Se sabe que estos anticuerpos monoclonales reconocen epítopos conformacionales presentes en correceptores de VIH-1 (Lee B et al., J Biol. Chem., 1999; Baribaud F et al., J Virol. 2001). Por consiguiente, cualquier reconocimiento de Tat por estos anticuerpos indicaría que Tat comparte similitud estructural con el correceptor relevante.
Se revistieron placas de ELISA con Tat nativa o uno de los siguientes péptidos de Tat (la región o regiones a las que corresponden esencialmente estos péptidos se indica entre paréntesis):
Tat (1-20) (dominio N-terminal);
Tat (21-40) (región rica en cisteína -dominio de transactivación);
Tat (36-50) (región del núcleo);
Tat (46-60) (región básica -señal de localización nuclear);
Tat (56-70) (región rica en glutamina);
Tat (65-80) (secuencia RGD);
Tat (73-86) (secuencia RGD);
Tat (83-102) (dominio C-terminal); y
Tat (21-58) (cisteína, núcleo y regiones básicas).
Se usaron anticuerpos monoclonales anti-CCR5 o anti CXCR4 para la etapa de detección. El anti-CCR5 reconocía específicamente la proteína Tat nativa recombinante, el péptido de Tat (21-58) y, aunque con una menor eficiencia, el péptido de Tat (46-60). Los resultados se muestran en la tabla 2, a continuación. En contraste, no se observó ningún reconocimiento con los anticuerpos dirigidos contra CXCR4.
TABLA 2
Revestimiento
Anticuerpos
anti-CCR5
anti-CXCR4 CTR isot. anti-Tat
Tat
1,452 0,085 0,081 3,000
Tat 1-20
0,000 0,000 0,006 3,000
Tat 21-40
0,000 0,133 0,082 0,1
Tat 36-50
0,000 0,000 0,000 0,000
Tat 46-60
0,466 0,000 0,063 0,000
Tat 56-70
0,147 0,000 0,000 0,75
9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
ES05729962.0T 2004-03-11 2005-03-11 Nuevos complejos Tat, y vacunas que los comprenden Active ES2535681T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0405480.5A GB0405480D0 (en) 2004-03-11 2004-03-11 Novel tat complexes,and vaccines comprising them
GB0405480 2004-03-11
PCT/EP2005/003043 WO2005090391A1 (en) 2004-03-11 2005-03-11 Novel tat complexes, and vaccines comprising them

Publications (1)

Publication Number Publication Date
ES2535681T3 true ES2535681T3 (es) 2015-05-13

Family

ID=32117467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05729962.0T Active ES2535681T3 (es) 2004-03-11 2005-03-11 Nuevos complejos Tat, y vacunas que los comprenden

Country Status (13)

Country Link
US (1) US9969780B1 (es)
EP (1) EP1723169B1 (es)
JP (1) JP4714213B2 (es)
CN (1) CN1930184B (es)
AU (1) AU2005223352B2 (es)
CA (1) CA2556080C (es)
DK (1) DK1723169T3 (es)
ES (1) ES2535681T3 (es)
GB (1) GB0405480D0 (es)
IL (1) IL177223A (es)
NZ (1) NZ549082A (es)
RU (1) RU2432356C2 (es)
WO (1) WO2005090391A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2001508A2 (en) * 2006-03-28 2008-12-17 Novartis Ag Covalently-linked complexes of hiv tat and env proteins
CA2647942A1 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US7943140B2 (en) 2006-08-14 2011-05-17 Thymon, Llc Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
CA2697370A1 (en) * 2007-08-24 2009-03-05 Novartis Ag Hiv env proteins with modifications in the v3 loop
GB201004656D0 (en) 2010-03-19 2010-05-05 Ensoli Barbara Immune therapy
WO2023038462A1 (ko) * 2021-09-10 2023-03-16 연세대학교 산학협력단 Tat 펩타이드 변이체를 유효성분으로 포함하는 대사질환의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0567643A4 (en) 1991-01-16 1995-07-19 Yoshitomi Pharmaceutical PYRIDINE COMPOUND USED AS A SELECTIVE DRUG AND NEW PYRIDINE COMPOUND.
PL211762B1 (pl) * 2000-01-31 2012-06-29 Smithkline Beecham Biolog Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
JP2001286284A (ja) 2000-04-05 2001-10-16 Nobuo Sato 腫瘍特異抗原を用いた腫瘍の遺伝子診断剤・遺伝子治療剤およびプロトンポンプ阻害剤の抗腫瘍治療剤としての新規応用
WO2002080917A1 (en) 2001-04-06 2002-10-17 Forskarpatent I Uppsala Ab Novel use of proton pump inhibitors
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
JP2003277262A (ja) 2002-03-18 2003-10-02 ▲寛▼治 ▲高▼田 ランソプラゾールのバイオアベイラビリティ改善技術
EP1431306A1 (en) 2002-12-19 2004-06-23 Creabilis Therapeutics s.r.l. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
GB0225786D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines

Also Published As

Publication number Publication date
CA2556080A1 (en) 2005-09-29
CN1930184A (zh) 2007-03-14
CA2556080C (en) 2016-05-10
CN1930184B (zh) 2012-11-28
EP1723169A1 (en) 2006-11-22
RU2006129097A (ru) 2008-02-20
WO2005090391A1 (en) 2005-09-29
IL177223A (en) 2015-10-29
NZ549082A (en) 2009-11-27
EP1723169B1 (en) 2015-01-07
JP4714213B2 (ja) 2011-06-29
DK1723169T3 (en) 2015-04-20
GB0405480D0 (en) 2004-04-21
US9969780B1 (en) 2018-05-15
AU2005223352B2 (en) 2010-05-20
RU2432356C2 (ru) 2011-10-27
AU2005223352A1 (en) 2005-09-29
JP2007535500A (ja) 2007-12-06
IL177223A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
Moore et al. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
Yang et al. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
ES2535681T3 (es) Nuevos complejos Tat, y vacunas que los comprenden
Finnegan et al. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion
US8110203B2 (en) Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes
He et al. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors
Zhu et al. Design and characterization of cholesterylated peptide HIV-1/2 fusion inhibitors with extremely potent and long-lasting antiviral activity
Yang et al. Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
Siddappa et al. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein
VanCott et al. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope
Kwong et al. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein
US6008044A (en) Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
Parajuli et al. Lytic inactivation of human immunodeficiency virus by dual engagement of gp120 and gp41 domains in the virus Env protein trimer
US6042831A (en) Human immunodeficiency virus type 1 (HIV-1) GP160 epitopes that are immunologically homologous to epitopes located in the class I major histocompatibility complex (MHC) heavy chain α-1 domain
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
Liao et al. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
Howie et al. Synthetic peptides representing discontinuous CD4 binding epitopes of HIV‐1 gp120 that induce T cell apoptosis and block cell death induced by gp120
Billington et al. Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding
Ling et al. The N-terminal of the V3 loop in HIV type 1 gp120 is responsible for its conformation-dependent interaction with cell surface molecules
Chen et al. Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate
Cotton et al. Design and synthesis of a highly immunogenic, discontinuous epitope of HIV-1 gp120 which binds to CD4+ ve transfected cells
DUBOIS et al. Expression and purification of protein segments encoded by the envelope and 3′-orf genes of human immunodeficiency virus type 1
Tamamura et al. Peptidomimetics That Mimic the Tertiary Structures of Peptides
Huisman et al. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations
Jrad et al. Linear and cyclic peptides mimicking the disulfide loops in HIV-2 envelope glycoprotein induced antibodies with different specificity